INTRODUCTION
Hodgkin's lymphoma (HL) is a rare B-cell malignancy involving lymph nodes and the lymphatic system. It accounts for 3.6% of all cancers in Saudi Arabia, with 436 new cases in 2015. In HL, there is a slight male predominance, and it is the seventh and eight most common cancer among Saudi males and females, respectively. In 2015, the age-standardized rate was 2.6/100,000 for males and 1.7/100,000 for females. In addition, the median age at diagnosis was 26 years in both genders (range among males: 3-84 years; females: 4-89 years). [1] 
METHODS
A committee comprising experts in hematology and medical oncology was established under the supervision of the Saudi Lymphoma Group and in collaboration with the Saudi Oncology Society. For collecting evidence, a literature search was carried out with relevant keywords using online database search engines such as PubMed/Medline, Web of Science and Scopus. In addition, expert opinion was considered when necessary. The levels of evidence used in developing this guideline were as follows:
• Evidence level (EL)-1 (highest), evidence from Phase III randomized trials or meta-analyses • EL-2 (intermediate), evidence from well-designed Phase II trials or Phase III trials with limitations • EL-3 (low), evidence from retrospective or observational studies/reports and/or expert opinion.
This easy-to-follow grading system is convenient for readers to understand and allows an accurate assessment of the guideline's applicability in individual patients. [2] 1. DIAGNOSIS AND WORK-UP 1.1. The diagnostic work up for HL patients has evolved since the introduction of positron emission tomography-computed tomography (PET/CT) scanning. In patients undergoing PET/CT evaluation, a bone marrow biopsy is not indicated. However, if PET/CT is not available, bone marrow biopsy should be carried out in patients with advanced stage disease, B-symptoms and/or abnormal complete blood count (CBC) (EL-1) [3] [4] [5] 1.2. A diagnostic assessment based solely on fine needle aspiration is insufficient (EL-3) [6] [7] [8] 1.3. Before initiating treatment, cardiac and pulmonary function tests should be carried out to identify patients at increased risk of acute or chronic complications. In addition, young patients should be offered reproductive counseling before the treatment is initiated, as chemo-and radiotherapy can permanently impair fertility 1.4. Summary of the diagnostic work-up (EL-1). [3] [4] [5] 9, 10] and CD15, occasionally positive for CD20 and negative for CD45, whereas in NLPHL, malignant cells are positive for CD20 and CD45, but negative for CD15 and CD30 (EL-1). [12] 3. STAGING 3. [13] [14] [15] [16] [17] [18] 4.1.2. ABVD alone is also an effective treatment modality, especially among younger patients (i.e., <60 years old) who achieve complete remission after two cycles, according to the interim PET/CT (Deauville score of 1-3).
In these patients, there should only be subsequent one or two cycles of ABVD (i.e., a total of three to four cycles of ABVD) to avoid the long-term risks of radiotherapy (EL-1) [15, [19] [20] [21] [22] [23] [24] 4. 
Refractory/Relapsed disease
Most patients with HL achieve complete remission and long-term disease control with standard management approach. However, relapse may occur in about 10% of patients with limited HL and in 15%-30% of patients with advanced HL. Approximately 10%-15% of patients may have refractory disease that either does not respond to standard therapy or progresses after an initial partial response (EL-1). [13, 18, 20, 23, 35] 4.3.1. A case of suspected relapse must be confirmed with a new biopsy, and obtaining a new biopsy should be considered in refractory disease 4.3.2. In some patients with a localized late relapse, salvage radiotherapy alone is likely to be sufficient (EL-3) [37] 4.3.3. In most patients with relapsed or refractory HL, the preferred treatment modality comprises platinum-based or brentuximab vedotin-containing regimen followed by high-dose chemotherapy and ASCT (EL-2). [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] 4.3.3.1 Salvag e regimens such as GDP (gemcitabine, dexamethasone, and cisplatin); [49] 
DICEP (dose-intensive c y c l o p h o s p h a m i d e , e t o p o s i d e , cisplatin)
; [42, 43] ESHAP (etoposide, methylprednisolone (solumedrol), high-dose cytarabine (ara-C) and cisplatin (platinum chemotherapy); [50] DHAP (dexamethasone, cytarabine, cisplatin); [40] IGEV (ifosfamide, gemcitabine, and vinorelbine); [41] ICE (ifosamide, carboplatin, and etoposide); [51] B-ICE (brentuximab vedotin plus ifosamide, carboplatin, and etoposide; [52] 
), high-dose cytarabine (ara-C) and cisplatin (platinum chemotherapy); [53] BeGEV (bendamustine, gemcitabine and vinorelbine) or BvB (Brentuximab vedotin and bendamustine) [54, 55] have been shown to reduce the disease burden and mobilize stem cells before high-dose chemotherapy and ASCT. However, no comparative trails have shown any salvage approach to be superior than the others (EL-2). 4.3.3.2. Several conditioning regimes such as BEAM (carmustine, etoposide, cytarabine, melphalan) or single agent high-dose melphalan have also been used (EL-3). [39, [45] [46] [47] 4.3.3.3. The use of brentuximab vedotin as maintenance therapy for 1 year after ASCT is highly recommended for high-risk patients (primar y refractory, patients who relapsed within 12 months, relapse with extra-nodal disease or pre-transplant positive PET/ CT) (EL-2). [44, 48] 4.3.4. Following ASCT, in responding patients found to have localized residual disease on PET, a consolidative radiotherapy to the active site is recommended (EL-3). 4.3.5. Patients who experience a relapse following ASCT have been shown to respond to the following treatment options (EL-2): 3.2.5.1. Brentuximab vedotin [55, 56] 3.2.5.2. Nivolumab [57, 58] 3.2.5.3. Pembrolizumab [59] 3.2.5.4. Allogeneic stem cell transplantation (in young patients with good general condition). [60] 
M A N A G E M E N T O F N O D U L A R
LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA NLPHL has a similar natural history to indolent lymphomas. As NLPHL cells consistently express CD20, addition of an anti-CD20 therapy improves treatment efficacy; currently, data provides support for the use of rituximab. [61] 5. 
TREATMENT RESPONSE EVALUATION AND LONG-TERM FOLLOW UP (EL-3)
6.1. The preferred imaging modality for assessing the response to therapy is PET/CT. This is typically first ("interim") done after the initial two cycles of chemotherapy and 6-8 weeks after completing chemotherapy/ASCT or 8-12 weeks after completing radiotherapy. After completion of treatment, follow-up assessments are mainly focused on monitoring for recurrence and late side effects. In long-term survivors, the most serious late side effects are secondary cancers, hypothyroidism, cardiovascular diseases and fertility issues. The incidence of these late side effects is directly proportional to the duration of follow-up; nonetheless, the current treatment protocols are likely to have lesser side effects compared with those used >10 years ago. However, it is recommended that patients are encouraged to seek counseling regarding survivorship, long-term treatment effects, health habits and psychosocial issues. 6.1.1. The follow-up schedule after achieving remission: 6.1.1.1.1 Every 3 months for 2 years, then every 6 months for 3 years, and then annually 6.1.1.1.2. History and physical examination should be documented in every visit 6.1.1.1.3. CBC with differential count, erythrocyte sedimentation rate and LFT should be requested in every visit 6.1.1.1.4. TSH test should be carried out at least once annually if the patient received radiotherapy to the neck 6.1.1.1.5. Annual influenza immunization is recommended 6.1.1.1.6. Chest X-ray should be performed at each visit in the first 2 years, and then at every other visit, especially for patients who previously had intrathoracic disease 6.1.1.1.7. Mammogram or MRI of breast is required for women who received chest radiotherapy, beginning 10 years after diagnosis of lymphoma or when aged 40 years, whichever comes first 6.1.1.1.8. Pap smear is recommended.
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